"Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt

Inclusion Criteria: * HCV RNA positivity * 18 years =\< Age =\< 70 years * Patients \>= 65 years should undergo cardiological assessment prior to therapy by ECG echocardiography and cardiological consultation * Effective contraception (Women of childbearing potential should use an effective contraception; Male patients and their female partners must also practice effective contraception) both during treatment and for the 3-months post-therapy); no breast-feeding * Signed informed consent and willingness to participate in the study Exclusion Criteria: * Child C cirrhotic patients * Platelet count \> 50000/mm3 * Hepatocellular Carcinoma (HCC), except 6 months after intervention aiming at cure with no evidence of activity by dynamic imaging (CT or MRI) * Extra-hepatic malignancy except after two years of disease-free interval (in case of lymphomas and chronic lymphatic leukemia, treatment can be initiated immediately after remission) * Pregnancy or inability to use effective contraception * inadequately controlled diabetes mellitus (HbA1C\>9%)